Clinical trials: Mild Cognitive Impairment, Dementia
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
This study will investigate the performance of physician readers trained to read florbetapir-PET scans using electronic media training.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01550549
- Testing
- florbetapir F 18
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Computer-Based Training for Mild Alzheimer's Disease
The primary objective of this study is to evaluate the effects of computer-based training program ("HiFi-AD") on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer's Disease (AD).
- Trial name
- NCT00319891
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Posit Science Corporation
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Alzheimer Disease, Cognitive Impairment
Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium…
- Trial name
- NCT01453569
- Testing
- Sodium oligo-mannurarate 600mg, Sodium oligo-mannurarate 900mg
- Where
- 24 sites in China
- Volunteers
- 255 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Cognition Disorder, Nervous System Diseases
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
The purpose of this follow-up study is to assess the long-term safety and tolerability of galantamine in individuals with mild cognitive impairment who participated in a previous study with galantamine
- Conditions
- Cognition Disorder, Nervous System Diseases, Mental Disorders, Brain Diseases
- Trial name
- NCT00240695
- Testing
- galantamine hydrobromide
- Volunteers
- 724 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
Efficacy and Safety of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo
- Trial name
- NCT06761066
- Testing
- NVP-NK4146
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- NVP Healthcare
Neurological Diseases or Conditions, Dementia of Alzheimer Type
An Observational Study of Patients Living With Chronic Neurological Diseases
TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment…
- Conditions
- Neurological Diseases or Conditions, Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT05796037
- Volunteers
- 1,500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alzheimer's Disease
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00454870
- Testing
- MEM 3454
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memory Pharmaceuticals
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer´s Disease
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
- Trial name
- AD Biomarker (NCT07741526)
- Testing
- NPI-001
- Where
- 4 sites in Denmark, Iceland
- Volunteers
- 33 people
- Sponsor
- Arctic Therapeutics
Alzheimer's Disease, Mild Cognitive Impairment
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose study of ABT-957 in participants with mild Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) due to AD.
- Trial name
- NCT02573740
- Testing
- ABT-957
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- AbbVie
Alzheimer Disease, Alzheimer Disease, Early Onset
A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood…
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss
- Trial name
- NCT04733989
- Testing
- Biomarker Data Collection
- Where
- 16 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- GAP Innovations, PBC
Parkinson Disease
Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
This is a pilot randomized, sham-controlled, double-blind, multi-center study evaluating the safety and preliminary effectiveness of the Gen0Bh Transcranial Focused Ultrasound System for the treatment of motor symptoms in…
- Trial name
- NCT07207122
- Testing
- Gen0Bh Transcranial Focused Ultrasound System (Active)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sanmai Technologies PBC dba Sanmai
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Alzheimer Disease
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Trial name
- RESOLVE (NCT07633470)
- Testing
- Zunveyl®
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Alpha Cognition, Inc
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Mild Cognitive Impairment, Alzheimer's Disease
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
REINVENT is a non-interventional, multi-center, research network-based cross-over study evaluating the potential utility of a telehealth platform in improving the efficiency of clinical trials.
- Trial name
- REINVENT (NCT02778438)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Quintiles, Inc.